Beyond Better, Faster, Cheaper—The Human Face of AI Drug Repurposing 

Most of the time, when we sit down to write these articles each month, we focus on the interplay of technology and science, delivering AI de novo molecule discovery and AI drug repurposing. 

We talk about how the scientific AI revolution promises new treatments which are more effective, and faster and cheaper to develop than traditional methods. What we don't talk much about, however, is the people. Not all of you amazing researchers who are out there doing this wildly important work, but instead, the people for whom, in the end, all this work is designed to help—the patients.  

One of the scientists who have long inspired us for their tenacity and brilliance is David Fajgenbaum. For those who haven't heard of him, Dr. David Fajgenbaum, physician, researcher, and professor at the University of Pennsylvania, became widely known after successfully diagnosing and treating his own rare illness, Castleman disease, a life-threatening immune disorder. His experience inspired him to pioneer a global initiative using artificial intelligence and advanced data analysis to perform AI drug repurposing to identify existing drugs that could treat rare diseases, transforming his personal fight into a broader mission to help others facing similarly devastating conditions. 

The Human Face of What We Do 

Recently, we came across this excellent article by Kate Morgan of the New York Times that once again highlighted the important work being done across the globe in AI drug repurposing, with an emotional shot in the arm reminding us of why we all come to work in the morning. The article tells the story of Joseph Coates, who, at just 37 years old and battling a rare blood disorder known as POEMS syndrome, was told he was going to die. 

Too ill for a potentially life-saving stem cell transplant, Joseph had begun to accept his death as inevitable. His partner, Tara Theobald, however, wasn't ready to give up and reached out, in love and desperation, to Dr. Fajgenbaum, whom they had encountered at a rare disease conference. Dr. Fajgenbaum responded with a cocktail of chemotherapy, immunotherapy, and steroids, recommended by his AI drug repurposing technology. With nothing to lose, and a supportive medical team, Joseph started the AI-recommended regimen, and within days was showing astonishing improvement. Within months, he was healthy enough to undergo a stem cell transplant, and today he is living in remission.  

Beyond Better, Faster, Cheaper—The Real Mission is Life 

It's easy as researchers and technologists to be so focused on what we are doing that we fail to raise our eyes to the horizon to remember the mission and see the true human face of its results. Stories like Joseph's remind us why AI drug repurposing matters so deeply, not just because they demonstrate how we are pushing the boundaries of scientific and technological achievement, but because of what it ultimately means for real people, real families, and real lives. Behind every data set, every algorithm, every breakthrough, there is a person who dreams of more days with their children, more sunsets with their partner, more laughter with their friends. Behind all of it, there is life. 

AI-driven drug repurposing is about hope; it's about taking what we already know and flipping it to offer something tangible and life-changing. For countless others living with rare or hard-to-treat diseases, it represents a chance at survival, healing, love, joy, and futures that these illnesses threaten to steal away.  

Turning toward the human face of AI drug discovery and AI drug repurposing reminds us that our work has meaning far beyond scientific curiosity and the thrill of creating groundbreaking technology and treatments. In the AI field, each innovation and every new or improved discovery that is made faster and cheaper, translates directly into lives saved. What we do isn't merely a scientific pursuit-it's deeply human. It's about hope and the relentless pursuit of possibilities that once seemed impossible. It's about ensuring that when families like Joseph and Tara's face their darkest moments, science and technology are there to light a path forward. 

Accencio transforms how data can be used in molecular research. If you would like to learn more about how we can make this a reality for you, contact us.